Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study

Creative Commons License

Yamamoto-Furusho J. K., Al Harbi O., Armuzzi A., Chan W., de Leon E. P., Qian J., ...Daha Fazla

DIGESTIVE AND LIVER DISEASE, cilt.52, sa.8, ss.869-877, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 52 Sayı: 8
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.dld.2020.05.031
  • Dergi Adı: DIGESTIVE AND LIVER DISEASE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.869-877
  • Anahtar Kelimeler: Ulcerative colitis, Crohn's disease, Anti-tumor necrosis factor, Suboptimal response, TAIWAN CONSENSUS GUIDELINE, ANTI-TNF THERAPY, ULCERATIVE-COLITIS, INDUCTION THERAPY, MANAGEMENT, CROHNS, ADALIMUMAB, INFLIXIMAB, SOCIETY, IBD
  • Ankara Üniversitesi Adresli: Evet

Özet

Background: Incidence of inflammatory bowel disease (IBD) is increasing in newly industrialised countries (NICs); however, data on suboptimal response to anti-tumor necrosis factor (anti-TNF) agents are limited.